Sutro Biopharma, Inc. (STRO): Price and Financial Metrics


Sutro Biopharma, Inc. (STRO): $4.50

0.06 (+1.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

STRO POWR Grades


  • STRO scores best on the Sentiment dimension, with a Sentiment rank ahead of 67.8% of US stocks.
  • STRO's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • STRO ranks lowest in Momentum; there it ranks in the 8th percentile.

STRO Stock Summary

  • STRO's went public 3.51 years ago, making it older than merely 11.48% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of 133.75%, Sutro Biopharma Inc's debt growth rate surpasses 92.3% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Sutro Biopharma Inc is reporting a growth rate of 265.05%; that's higher than 91.94% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sutro Biopharma Inc are CAPR, YMAB, FDMT, SLDB, and BCDA.
  • STRO's SEC filings can be seen here. And to visit Sutro Biopharma Inc's official web site, go to www.sutrobio.com.

STRO Valuation Summary

  • In comparison to the median Healthcare stock, STRO's price/sales ratio is 284.21% higher, now standing at 14.6.
  • Over the past 36 months, STRO's price/sales ratio has gone up 8.1.
  • STRO's price/earnings ratio has moved up 4.4 over the prior 36 months.

Below are key valuation metrics over time for STRO.

Stock Date P/S P/B P/E EV/EBIT
STRO 2021-08-31 14.6 3.3 -12.7 -12.6
STRO 2021-08-30 14.5 3.3 -12.7 -12.5
STRO 2021-08-27 14.6 3.3 -12.7 -12.6
STRO 2021-08-26 13.8 3.1 -12.1 -11.9
STRO 2021-08-25 13.6 3.0 -11.9 -11.7
STRO 2021-08-24 13.7 3.1 -11.9 -11.8

STRO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STRO has a Quality Grade of D, ranking ahead of 10.85% of graded US stocks.
  • STRO's asset turnover comes in at 0.194 -- ranking 205th of 680 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows STRO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.194 1 -0.301
2021-03-31 0.150 1 -0.169
2020-12-31 0.151 1 -0.155
2020-09-30 0.204 1 0.118
2020-06-30 0.212 1 -0.081
2020-03-31 0.246 1 -0.444

STRO Price Target

For more insight on analysts targets of STRO, see our STRO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.71 Average Broker Recommendation 1.38 (Strong Buy)

STRO Stock Price Chart Interactive Chart >

Price chart for STRO

STRO Price/Volume Stats

Current price $4.50 52-week high $23.70
Prev. close $4.44 52-week low $4.32
Day low $4.38 Volume 30,834
Day high $4.53 Avg. volume 560,206
50-day MA $6.83 Dividend yield N/A
200-day MA $13.41 Market Cap 211.20M

Sutro Biopharma, Inc. (STRO) Company Bio


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.


STRO Latest News Stream


Event/Time News Detail
Loading, please wait...

STRO Latest Social Stream


Loading social stream, please wait...

View Full STRO Social Stream

Latest STRO News From Around the Web

Below are the latest news stories about Sutro Biopharma Inc that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Does Sutro Biopharma (NASDAQ:STRO) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Yahoo | February 18, 2022

Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […]

Yahoo | February 17, 2022

7 Triple-F-Rated Stocks That Have No Hope in Sight

The contrarian in a lot of people perks up during selloffs like the one we're in right now, but don't let these F-rated stocks tempt you.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | February 7, 2022

Implied Volatility Surging for Sutro Biopharma (STRO) Stock Options

Investors need to pay close attention to Sutro Biopharma (STRO) stock based on the movements in the options market lately.

Yahoo | January 7, 2022

Berenberg Bank Thinks Sutro Biopharma’s Stock is Going to Recover

Berenberg Bank analyst Zhiqiang Shu maintained a Buy rating on Sutro Biopharma (STRO – Research Report) today and set a price target of $30.00. The company's shares closed last Wednesday at $14.57, close to its 52-week low of $14.26. According to TipRanks.com, Shu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.8% and a 26.6% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sutro Biopharma with a $31.00 average price target.

Howard Kim on TipRanks | January 6, 2022

Read More 'STRO' Stories Here

STRO Price Returns

1-mo -33.53%
3-mo -49.32%
6-mo -72.19%
1-year -75.87%
3-year -56.61%
5-year N/A
YTD -69.76%
2021 -31.46%
2020 97.36%
2019 21.95%
2018 N/A
2017 N/A

Continue Researching STRO

Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:

Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.1061 seconds.